Healthcare Industry News:  Uterine Fibroids 


 News Release - June 28, 2016

Halt Medical, Inc. Announces The First Acquisition Of Acessa Guidance System

BRENTWOOD, Calif., June 27, 2016 -- (Healthcare Sales & Marketing Network) -- Halt Medical, Inc. announced today that Trinity Park Surgery Center, Arlington, TX, is the first facility in the United States to acquire the Acessa® Guidance System1.

"We are honored to be partnering with a facility that is passionate about investing in a fibroid treatment center of excellence," said Kim Bridges, Halt Medical President and CEO.

"At Trinity Park Surgery Center, we pride ourselves in offering the most advanced, minimally invasive platforms," added Jessica Doll, Administrator (BSN, RN). "This technology is an important advancement in the field of gynecology. We wanted to be the first in the United States to make it readily available to our physicians and patients."

The Acessa Guidance System incorporates electromagnetic tracking technology and radiofrequency ablation to treat symptomatic Uterine Fibroids laparoscopically. When coupled with ultrasound, it provides instant feedback of device trajectory to the targeted fibroid and tracks the surgical instruments in real time.

"Hysterectomy and myomectomy are not always the answer for women with heavy bleeding and pain. The Acessa Guidance System provides women with symptomatic Uterine Fibroids more treatment options. After using Acessa for nearly two years, it's become a standard of care in my practice," said Dr. Kimberly Lefholz, Matlock OB/GYN, Arlington, TX. Dr. Lefholz was also the first gynecologist in the United States to treat a patient commercially with the Acessa Guidance System.

About Halt Medical, Inc.

Founded in 2004, Halt Medical is a medical device company focused on establishing a new standard of care for women with symptomatic Uterine Fibroids. The Company has developed and launched the Acessa System and Procedure, using radiofrequency energy to destroy Uterine Fibroids. The results of both U.S. and international trials have led to the clearance of the product by the FDA for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic Uterine Fibroids under laparoscopic ultrasound guidance. The Company is located in Brentwood, CA.

1 Patented Aim™ guidance software provided by InnerOptic Technology, Inc.

Source: Halt Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.